keyword
MENU ▼
Read by QxMD icon Read
search

Xpert MTB

keyword
https://www.readbyqxmd.com/read/28320384/diagnostic-accuracy-incremental-yield-and-prognostic-value-of-determine-tb-lam-for-routine-diagnostic-testing-for-tuberculosis-in-hiv-infected-patients-requiring-acute-hospital-admission-in-south-africa-a-prospective-cohort
#1
Stephen D Lawn, Andrew D Kerkhoff, Rosie Burton, Charlotte Schutz, Andrew Boulle, Monica Vogt, Ankur Gupta-Wright, Mark P Nicol, Graeme Meintjes
BACKGROUND: We previously reported that one-third of HIV-positive adults requiring medical admission to a South African district hospital had laboratory-confirmed tuberculosis (TB) and that almost two-thirds of cases could be rapidly diagnosed using Xpert MTB/RIF-testing of concentrated urine samples obtained on the first day of admission. Implementation of urine-based, routine, point-of-care TB screening is an attractive intervention that might be facilitated by use of a simple, low-cost diagnostic tool, such as the Determine TB-LAM lateral-flow rapid test for HIV-associated TB...
March 21, 2017: BMC Medicine
https://www.readbyqxmd.com/read/28317811/performance-of-the-xpert-mtb-rif-assay-in-the-diagnosis-of-tuberculosis-in-formalin-fixed-paraffin-embedded-tissues
#2
Pascal Polepole, Mwila Kabwe, Mpanga Kasonde, John Tembo, Aaron Shibemba, Justin O'Grady, Nathan Kapata, Alimuddin Zumla, Matthew Bates
OBJECTIVE/BACKGROUND: Extrapulmonary tuberculosis (EPTB), which accounts for 10%-40% of the global burden of TB, with the highest incidence in Sub-Saharan Africa, is strongly associated with human immunodeficiency virus infection. Diagnosing EPTB is challenging, and recently, there has been a concerted effort to evaluate the latest molecular diagnostics for diagnosing TB in a range of specimen types. The Xpert MTB/RIF assay (Cepheid, Sunnyvale, CA, USA) is one such technology, which simultaneously detects Mycobacterium tuberculosis and rifampicin resistance...
January 2017: International Journal of Mycobacteriology
https://www.readbyqxmd.com/read/28284274/initial-screening-of-extra-pulmonary-tuberculosis-using-the-xpert-mtb-rif-assay-improves-case-detection-rates
#3
Amita Jain, Pravin Kumar Singh, Urmila Singh, Vijay Kumar
No abstract text is available yet for this article.
April 1, 2017: International Journal of Tuberculosis and Lung Disease
https://www.readbyqxmd.com/read/28284253/effect-of-previous-treatment-and-sputum-quality-on-diagnostic-accuracy-of-xpert-%C3%A2-mtb-rif
#4
C Acuña-Villaorduña, P Orikiriza, D Nyehangane, L F White, J Mwanga-Amumpaire, S Kim, M Bonnet, K P Fennelly, Y Boum, E C Jones-López
SETTING: In early studies, Xpert® MTB/RIF accurately detected culture-proven pulmonary tuberculosis (TB). Recent reports have, however, found a lower than expected specificity in previously treated TB patients. OBJECTIVE: To investigate the diagnostic accuracy of Xpert in presumptive pulmonary TB patients in Southwestern Uganda. DESIGN: We obtained demographic and clinical information and collected three sputum samples from each patient for smear microscopy, Xpert and culture...
April 1, 2017: International Journal of Tuberculosis and Lung Disease
https://www.readbyqxmd.com/read/28284252/operational-modelling-the-mechanisms-influencing-tb-diagnostic-yield-in-an-xpert-%C3%A2-mtb-rif-based-algorithm
#5
R Dunbar, P Naidoo, N Beyers, I Langley
SETTING: Cape Town, South Africa. OBJECTIVE: To compare the diagnostic yield for smear/culture and Xpert® MTB/RIF algorithms and to investigate the mechanisms influencing tuberculosis (TB) yield. METHOD: We developed and validated an operational model of the TB diagnostic process, first with the smear/culture algorithm and then with the Xpert algorithm. We modelled scenarios by varying TB prevalence, adherence to diagnostic algorithms and human immunodeficiency virus (HIV) status...
April 1, 2017: International Journal of Tuberculosis and Lung Disease
https://www.readbyqxmd.com/read/28284251/bottom-up-or-top-down-unit-cost-estimation-of-tuberculosis-diagnostic-tests-in-india
#6
S Rupert, A Vassall, N Raizada, S D Khaparde, C Boehme, V S Salhotra, K S Sachdeva, S A Nair, A H Van't Hoog
SETTING: Of 18 sites that participated in an implementation study of the Xpert® MTB/RIF assay in India, we selected five microscopy centres and two reference laboratories. OBJECTIVE: To obtain unit costs of diagnostic tests for tuberculosis (TB) and drug-resistant TB. DESIGN: Laboratories were purposely selected to capture regional variations and different laboratory types. Both bottom-up and the top-down methods were used to estimate unit costs...
April 1, 2017: International Journal of Tuberculosis and Lung Disease
https://www.readbyqxmd.com/read/28281441/miliary-tuberculosis
#7
Surendra K Sharma, Alladi Mohan
Miliary tuberculosis (TB) results from a massive lymphohematogenous dissemination of Mycobacterium tuberculosis bacilli and is characterized by tiny tubercles evident on gross pathology resembling millet seeds in size and appearance. The global HIV/AIDS pandemic and widespread use of immunosuppressive drugs and biologicals have altered the epidemiology of miliary TB. Considered to be predominantly a disease of infants and children in the pre-antibiotic era, miliary TB is increasingly being encountered in adults as well...
March 2017: Microbiology Spectrum
https://www.readbyqxmd.com/read/28275073/rapid-detection-of-cell-free-mycobacterium-tuberculosis-dna-in-tuberculous-pleural-effusion
#8
Nanying Che, Xinting Yang, Zichen Liu, Kun Li, Xiaoyou Chen
Tuberculous pleurisy is one of the most common extra-pulmonary tuberculosis, but its diagnosis remains to be difficult. In this study, we for the first time report detection of cell-free Mycobacterium tuberculosis DNA in pleural effusion and evaluation of this newly developed molecular assay. A total of 78 patients with pleural effusion, 60 patients with tuberculous pleurisy and 18 patients with alternative diseases, were included in this study. Mycobacterial culture, Xpert MTB/RIF assay, adenosine deaminase assay, T-SPOT...
March 8, 2017: Journal of Clinical Microbiology
https://www.readbyqxmd.com/read/28249999/utility-of-second-generation-line-probe-assay-hain-mtbdrplus-directly-on-2-month-sputa-specimens-to-monitor-tuberculosis-treatment-response
#9
Neesha Rockwood, Justyna Wojno, Yonas Ghebrekristos, Mark P Nicol, Graeme Meintjes, Robert J Wilkinson
The utility of line probe assay (Genotype MTBDRplus) performed directly on 2-month sputa to monitor tuberculosis treatment response is unknown. We assessed if direct testing of 2-month sputa with MTBDRplus can predict 2-month culture conversion and long-term treatment outcome. Xpert® MTB/RIF-confirmed rifampicin-susceptible tuberculosis cases were recruited at tuberculosis diagnosis and followed up at 2 and 5-6 months. MTBDRplus was performed directly on 2-month sputa and on all positive culture isolates at 2 and 5-6 months...
March 1, 2017: Journal of Clinical Microbiology
https://www.readbyqxmd.com/read/28237624/three-year-evaluation-of-xpert-mtb-rif-in-a-low-prevalence-tuberculosis-setting-a%C3%A2-scottish-perspective
#10
Benjamin J Parcell, Anna Jarchow-MacDonald, Amie-Louise Seagar, Ian Laurenson, Gordon J Prescott, Michael Lockhart
OBJECTIVES: Xpert MTB/RIF (Cepheid) is a rapid molecular assay shown to be sensitive and specific for pulmonary tuberculosis (TB) diagnosis in highly endemic countries. We evaluated its diagnostic performance in a low TB prevalence setting, examined rifampicin resistance detection and quantitative capabilities predicting graded auramine microscopy and time to positivity (TTP) of culture. METHODS: Xpert MTB/RIF was used to test respiratory samples over a 3 year period...
February 22, 2017: Journal of Infection
https://www.readbyqxmd.com/read/28229100/diagnosis-of-tuberculosis-following-world-health-organization-recommended-criteria-in-severely-malnourished-children-presenting-with-pneumonia
#11
Mohammod Jobayer Chisti, Mohammed Abdus Salam, Abu S M S B Shahid, K M Shahunja, Sumon Kumar Das, Abu Syed Golam Faruque, Pradip Kumar Bardhan, Tahmeed Ahmed
Evidences on diagnosis of tuberculosis (TB) following the World Health Organization (WHO) criteria in children with severe acute malnutrition (SAM) are lacking. We sought to evaluate the WHO criteria for the diagnosis of TB in such children. In this prospective study, we enrolled SAM children aged <5 with radiological pneumonia. We collected induced sputum and gastric lavage for smear microscopy, mycobacterial culture, and Xpert MTB/RIF. Using the last 2 methods as the gold standard, we determined sensitivity, specificity, and positive and negative predictive values of WHO criteria (n = 388)...
2017: Global Pediatric Health
https://www.readbyqxmd.com/read/28225345/results-of-xpert-%C3%A2-mtb-rif-implementation-in-kyrgyzstan
#12
G Kurbaniyazova, M Joncevska, S Kalon, G Kalmambetova, T Mohr, A Toktogonova, K Takieva, K M Monirul Islam, F Luelmo
INTRODUCTION: In July 2012, the United States Agency for International Development (USAID) Quality Health Care Project introduced the Xpert® MTB/RIF assay at the facility level of the primary health care system in Kyrgyzstan. This study analysed the results of the implementation of Xpert. MATERIALS AND METHODS: Test results from 2734 patients from July 2012 to December 2014 were analysed. The sensitivity and specificity of Xpert in routine programme conditions were evaluated using culture and phenotypic drug susceptibility testing (DST) as gold standard...
March 1, 2017: International Journal of Tuberculosis and Lung Disease
https://www.readbyqxmd.com/read/28225333/why-do-clinical-trials-of-xpert%C3%A2-mtb-rif-fail-to-show-an-effect-on-patient-relevant-outcomes
#13
T H Boyles
No abstract text is available yet for this article.
March 1, 2017: International Journal of Tuberculosis and Lung Disease
https://www.readbyqxmd.com/read/28222095/delays-and-loss-to-follow-up-before-treatment-of-drug-resistant-tuberculosis-following-implementation-of-xpert-mtb-rif-in-south-africa-a-retrospective-cohort-study
#14
Helen Cox, Lindy Dickson-Hall, Norbert Ndjeka, Anja Van't Hoog, Alison Grant, Frank Cobelens, Wendy Stevens, Mark Nicol
BACKGROUND: South Africa has a large burden of rifampicin-resistant tuberculosis (RR-TB), with 18,734 patients diagnosed in 2014. The number of diagnosed patients has increased substantially with the introduction of the Xpert MTB/RIF test, used for tuberculosis (TB) diagnosis for all patients with presumptive TB. Routine aggregate data suggest a large treatment gap (pre-treatment loss to follow-up) between the numbers of patients with laboratory-confirmed RR-TB and those reported to have started second-line treatment...
February 2017: PLoS Medicine
https://www.readbyqxmd.com/read/28214065/-contribution-of-the-xpert-mtb-rif-to-the-etiological-diagnosis-of-tuberculous-pleurisy
#15
N O Touré, M Wayzani, K Thiam, M F Cissé, F B Mbaye
INTRODUCTION: Performance of the Xpert MTB/RIF for the detection of Mycobacterium tuberculosis in pleural liquid is poorly described. The aim of this study was to determine its usefulness for the etiological diagnosis of a tuberculous pleurisy. PATIENTS AND METHOD: We performed a descriptive cross-sectional study, with analytical design, including all the patients having a unilateral serofibrinous pleurisy, exudative, lymphocytic, and sterile. The diagnosis of pleural tuberculosis was considered based on epidemiological, clinical, paraclinical and therapeutic arguments...
February 14, 2017: Revue des Maladies Respiratoires
https://www.readbyqxmd.com/read/28199520/implications-of-failure-to-routinely-diagnose-resistance-to-second-line-drugs-in-patients-with-rifampicin-resistant-tuberculosis-on-xpert-mtb-rif-a-multisite-observational-study
#16
Karen R Jacobson, Marinus Barnard, Mary B Kleinman, Elizabeth M Streicher, Elizabeth J Ragan, Laura F White, Ofer Shapira, Tania Dolby, John Simpson, Lesley Scott, Wendy Stevens, Paul D van Helden, Annelies Van Rie, Robin M Warren
No abstract text is available yet for this article.
February 12, 2017: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/28199375/has-universal-screening-with-xpert%C3%A2-mtb-rif-increased-the-proportion-of-multidrug-resistant-tuberculosis-cases-diagnosed-in-a-routine-operational-setting
#17
Pren Naidoo, Rory Dunbar, Judy Caldwell, Carl Lombard, Nulda Beyers
SETTING: Primary health services in Cape Town, South Africa where the introduction of Xpert® MTB/RIF (Xpert) enabled simultaneous screening for tuberculosis (TB) and drug susceptibility in all presumptive cases. STUDY AIM: To compare the proportion of TB cases with drug susceptibility tests undertaken and multidrug-resistant tuberculosis (MDR-TB) diagnosed pre-treatment and during the course of 1st line treatment in the previous smear/culture and the newly introduced Xpert-based algorithms...
2017: PloS One
https://www.readbyqxmd.com/read/28193240/substitution-of-ethambutol-with-linezolid-during-the-intensive-phase-of-treatment-of-pulmonary-tuberculosis-study-protocol-for-a-prospective-multicenter-randomized-open-label-phase-ii-trial
#18
Ji Yeon Lee, Deog Kyeom Kim, Jung-Kyu Lee, Ho Il Yoon, Ina Jeong, Eunyoung Heo, Young Sik Park, Jae Ho Lee, Sung Soo Park, Sang-Min Lee, Chang-Hoon Lee, Jinwoo Lee, Sun Mi Choi, Jong Sun Park, Joon-Sung Joh, Young-Jae Cho, Yeon Joo Lee, Se Joong Kim, Young Ran Hwang, Hyeonjeong Kim, Jongeun Ki, Hyungsook Choi, Jiyeon Han, Heejung Ahn, Seokyung Hahn, Jae-Joon Yim
BACKGROUND: Linezolid, an oxazolidinone, substantially improves treatment outcomes of multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis. We started a trial to test whether the use of linezolid instead of ethambutol could increase the rate of sputum culture conversion as of 8 weeks of treatment in patients with drug-susceptible tuberculosis. METHODS/DESIGN: This is a phase II, multicenter, randomized study with three arms. We are enrolling patients with pulmonary tuberculosis without rifampicin resistance screened by the Xpert MTB/RIF® assay...
February 13, 2017: Trials
https://www.readbyqxmd.com/read/28182705/low-implementation-of-xpert-mtb-rif-among-hiv-tb-co-infected-adults-in-the-international-epidemiologic-databases-to-evaluate-aids-iedea-program
#19
Kate Clouse, Meridith Blevins, Mary Lou Lindegren, Marcel Yotebieng, Dung Thi Nguyen, Alfred Omondi, Denna Michael, Djimon Marcel Zannou, Gabriela Carriquiry, April Pettit
OBJECTIVE: Xpert MTB/RIF is recommended by the World Health Organization (WHO) as the initial tuberculosis (TB) diagnostic test in individuals suspected of HIV-associated TB. We sought to evaluate field implementation of Xpert among a cohort of HIV/TB co-infected individuals, including availability, utilization and outcomes. DESIGN: Observational cohort study (patient-level data) and cross-sectional study (site-level Xpert availability data). METHODS: Data were collected at 30 participating International epidemiologic Databases to Evaluate AIDS (IeDEA) sites in 18 countries from January 2012-January 2016...
2017: PloS One
https://www.readbyqxmd.com/read/28172666/clinical-impact-and-cost-effectiveness-of-xpert-mtb-rif-testing-in-hospitalized-patients-with-presumptive-pulmonary-tuberculosis-in-the-united-states
#20
James F Cowan, Aldine S Chandler, Elizabeth Kracen, David R Park, Carolyn K Wallis, Emelline Liu, Chao Song, David H Persing, Ferric C Fang
No abstract text is available yet for this article.
February 15, 2017: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
keyword
keyword
23690
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"